Datar Genetics Limited

datarpgx.com

Datar Genetics Limited is a NABL and ISO 9001:2008 accredited Centre for Excellence in Genetics for providing innovative, comprehensive clinical management solutions in the domain of molecular genomics. We have fully integrated sequencing, bio-informatics, human interface and interpretation platforms with State of the Art technological capability to provide clinical applications. We provide the widest range of genetic solutions and analytics of 300+ high impact investigations across the domains of Oncology, Cardiology, Neurology, Diabetes, High Resolution HLA Typing and Matching, Reproductive Genetics, Neonatal Screening, Pharmacogenetics and many more.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

ABCELLERA AND ATLAS VENTURE COLLABORATE TO EMPOWER THE DEVELOPMENT OF IMPACTFUL MEDICINES FOR PATIENTS

AbCellera and Atlas Venture | August 04, 2022

news image

AbCellera and Atlas Venture announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company. The collaboration leverages Atlas’ proven track record in forming innovative biotechnology companies and AbCellera’s unique ability to quickly deliver lead drug candidates to bring transformational new medicines to patients faster. "Ab...

Read More

Cell and Gene Therapy

BIOTIMIZE ANNOUNCES THE OPENING OF A FUNDRAISING ROUND TO BUILD THE FIRST BIOLOGICAL CDMO IN BRAZIL

Biotimize | September 06, 2022

news image

Biotimize, a functional growth-stage biotechnology as a service company with a mission to transform lives through biotechnology, today announced the opening of a $30 million Series A fundraising round. The investment will enable Biotimize to build the first biological CDMO in Brazil and to become the first end-to-end biological CDMO in South America. Brazilian universities, startups, and medium-large companies face enormous challenges in developing biological Active Pharmaceutical...

Read More

MedTech, Industrial Impact

ATUM ANNOUNCES LICENSING DEAL WITH CODIAK FOR LEAP-IN TRANSPOSASE TECHNOLOGY

ATUM and Codiak | January 25, 2023

news image

On January 24, 2023, ATUM, a global leader in bioengineering solutions, announced that it has signed a comprehensive licensing agreement with Codiak BioSciences, a clinical-stage biopharmaceutical company, for the Leap-In Transposase® technology. ATUM will grant Codiak access to its Leap-In Transposase® technology in order to create mammalian cells expressing exosomes engineered to deliver therapeutic payloads under the conditions of the agreement. The Leap-In technology...

Read More

Industrial Impact

CELLARITY EXPANDS LEADERSHIP TEAM TO CONTINUE EVOLUTION OF A BREAKTHROUGH PLATFORM TO ENCODE BIOLOGY AND PURPOSEFULLY CREATE NEW MEDICINES

Cellarity | February 11, 2022

news image

Cellarity, a life sciences company founded by Flagship Pioneering to encode and simulate human biology to reimagine the way we create medicines, announced today the expansion of its executive leadership team with three key appointments. As Chief Scientific Officer, Laurens Kruidenier, Ph.D., will lead the continued evolution of Cellarity’s platform and pipeline and oversee cross functional integration across all aspects of computation, drug creation, and optimization. As Chief People Offic...

Read More
news image

Industrial Impact

ABCELLERA AND ATLAS VENTURE COLLABORATE TO EMPOWER THE DEVELOPMENT OF IMPACTFUL MEDICINES FOR PATIENTS

AbCellera and Atlas Venture | August 04, 2022

AbCellera and Atlas Venture announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company. The collaboration leverages Atlas’ proven track record in forming innovative biotechnology companies and AbCellera’s unique ability to quickly deliver lead drug candidates to bring transformational new medicines to patients faster. "Ab...

Read More
news image

Cell and Gene Therapy

BIOTIMIZE ANNOUNCES THE OPENING OF A FUNDRAISING ROUND TO BUILD THE FIRST BIOLOGICAL CDMO IN BRAZIL

Biotimize | September 06, 2022

Biotimize, a functional growth-stage biotechnology as a service company with a mission to transform lives through biotechnology, today announced the opening of a $30 million Series A fundraising round. The investment will enable Biotimize to build the first biological CDMO in Brazil and to become the first end-to-end biological CDMO in South America. Brazilian universities, startups, and medium-large companies face enormous challenges in developing biological Active Pharmaceutical...

Read More
news image

MedTech, Industrial Impact

ATUM ANNOUNCES LICENSING DEAL WITH CODIAK FOR LEAP-IN TRANSPOSASE TECHNOLOGY

ATUM and Codiak | January 25, 2023

On January 24, 2023, ATUM, a global leader in bioengineering solutions, announced that it has signed a comprehensive licensing agreement with Codiak BioSciences, a clinical-stage biopharmaceutical company, for the Leap-In Transposase® technology. ATUM will grant Codiak access to its Leap-In Transposase® technology in order to create mammalian cells expressing exosomes engineered to deliver therapeutic payloads under the conditions of the agreement. The Leap-In technology...

Read More
news image

Industrial Impact

CELLARITY EXPANDS LEADERSHIP TEAM TO CONTINUE EVOLUTION OF A BREAKTHROUGH PLATFORM TO ENCODE BIOLOGY AND PURPOSEFULLY CREATE NEW MEDICINES

Cellarity | February 11, 2022

Cellarity, a life sciences company founded by Flagship Pioneering to encode and simulate human biology to reimagine the way we create medicines, announced today the expansion of its executive leadership team with three key appointments. As Chief Scientific Officer, Laurens Kruidenier, Ph.D., will lead the continued evolution of Cellarity’s platform and pipeline and oversee cross functional integration across all aspects of computation, drug creation, and optimization. As Chief People Offic...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us